Literature DB >> 23290885

New treatment developments applied to elderly patients with advanced prostate cancer.

Deborah Mukherji1, Carmel J Pezaro, Ali Shamseddine, Johann S De Bono.   

Abstract

Prostate cancer is a common disease amongst elderly men. Compared with younger patients, men over the age of 75 are more likely to present with advanced disease and have a greater risk of death from prostate cancer despite higher death rates from competing causes. Treatment options for advanced prostate cancer have improved considerably in the last two years. The immunotherapy sipuleucel-T, the cytotoxic cabazitaxel, the androgen biosynthesis inhibitor abiraterone acetate, the radioisotope radium-223 and the antiandrogen enzalutamide have all been shown to improve survival in randomized phase III studies for patients with metastatic castration-resistant prostate cancer. This review will focus on the clinical data regarding new treatment developments specifically applied to elderly patients with advanced prostate cancer.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23290885     DOI： 10.1016/j.ctrv.2012.12.004

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


  6 in total

1.  Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer.

Authors:  Matthew R Smith; Dana E Rathkopf; Peter F A Mulders; Joan Carles; Hendrik Van Poppel; Jinhui Li; Thian Kheoh; Thomas W Griffin; Arturo Molina; Charles J Ryan
Journal:  J Urol       Date:  2015-07-04       Impact factor: 7.450

2.  Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data.

Authors:  Thomas W Flaig; Ravi C Potluri; Yvette Ng; Mary B Todd; Maneesha Mehra
Journal:  Cancer Med       Date:  2015-12-29       Impact factor: 4.452

3.  Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.

Authors:  Johann S de Bono; Matthew R Smith; Fred Saad; Dana E Rathkopf; Peter F A Mulders; Eric J Small; Neal D Shore; Karim Fizazi; Peter De Porre; Thian Kheoh; Jinhui Li; Mary B Todd; Charles J Ryan; Thomas W Flaig
Journal:  Eur Urol       Date:  2016-07-09       Impact factor: 20.096

4.  Sasanquasaponin inhibited epithelial to mesenchymal transition in prostate cancer by regulating the PI3K/Akt/mTOR and Smad pathways.

Authors:  Wenfeng Li; Yuanshen Mao; Bao Hua; Xin Gu; Chao Lu; Bin Xu; Weixin Pan
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

5.  Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.

Authors:  T Nelius; D Martinez-Marin; J Hirsch; B Miller; K Rinard; J Lopez; W de Riese; S Filleur
Journal:  Cell Death Dis       Date:  2014-05-08       Impact factor: 8.469

6.  No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer.

Authors:  Takeo Kosaka; Hiroshi Hongo; Keitaro Watanabe; Ryuichi Mizuno; Eiji Kikuchi; Mototsugu Oya
Journal:  Cancer Chemother Pharmacol       Date:  2018-10-03       Impact factor: 3.333
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.